pharma.economictimes.indiatimes

Biocon inks settlement with J&J arm to launch Stelara biosimilar in nine more markets

Biocon has secured a license to introduce its Stelara biosimilar in nine additional countries, expanding treatment access for ...
pharma.economictimes.indiatimes

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson's experimental prostate cancer drug, JNJ-6143, has shown significant tumor shrinkage and reduced PSA levels ...
pharma.economictimes.indiatimes

Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal

Zymeworks has entered a global licensing agreement with Roche to develop and commercialize its experimental lung cancer drug ...
pharma.economictimes.indiatimes

Amgen drug combined with immunotherapy extends survival in lung cancer trial

A groundbreaking study reveals that Amgen's Imdelltra, when combined with AstraZeneca's immunotherapy Imfinzi, significantly ...
pharma.economictimes.indiatimes

Takeda to seek Japan approval for gastric cancer drug next year

Takeda Pharmaceutical aims for regulatory approval in Japan for its promising gastric cancer drug, TAK-921, following ...
pharma.economictimes.indiatimes

AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds

AstraZeneca's late-stage trial data reveals significant improvements in overall survival for advanced stomach cancer patients using the drug sone-ve, outperforming chemotherapy and raising potential ...
pharma.economictimes.indiatimes

Patient group oppose Trehan’s place on Panel reviewing Pharma marketing Code

The inclusion of Dr. Naresh Trehan in a pharmaceutical marketing review panel faces backlash from patient groups over ...